Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingre Huayu Jianpi formula is a Traditional Chinese Medicine (TCM) compound developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is primarily investigated for the treatment of ulcerative colitis (UC) and the prevention of colitis-associated colon cancer (CAC). The formula is designed based on the TCM principles of clearing heat (Qingre), resolving blood stasis (Huayu), and strengthening the spleen (Jianpi). Mechanistically, it is studied for its ability to modulate the fibroblast-organoid niche, thereby influencing the intestinal microenvironment to suppress chronic inflammation and inhibit the malignant transformation of colonic epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingre huayu jianpi formula.